|
1
|
Lu KH and Broaddus RR: Endometrial cancer.
N Engl J Med. 383:2053–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paleari L, Pesce S, Rutigliani M, Greppi
M, Obino V, Gorlero F, Vellone VG and Marcenaro E: New insights
into endometrial cancer. Cancers (Basel). 13:14962021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saleh M, Virarkar M, Bhosale P, El Sherif
S, Javadi S and Faria SC: Endometrial cancer, the current
international federation of gynecology and obstetrics staging
system, and the role of imaging. J Comput Assist Tomogr.
44:714–729. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Javadian P and Nezhat F: Endometrial
carcinoma and its precursors. Adv Exp Med Biol. 1242:59–72. 2020.
View Article : Google Scholar
|
|
5
|
Friedenreich CM, Ryder-Burbidge C and
McNeil J: Physical activity, obesity and sedentary behavior in
cancer etiology: Epidemiologic evidence and biologic mechanisms.
Mol Oncol. 15:790–800. 2021. View Article : Google Scholar
|
|
6
|
Ryan NA, McMahon RF, Ramchander NC, Seif
MW, Evans DG and Crosbie EJ: Lynch syndrome for the gynaecologist.
Obstet Gynaecol. 23:9–20. 2021. View Article : Google Scholar
|
|
7
|
Kyo S and Nakayama K: Endometrial cancer
as a metabolic disease with dysregulated PI3K signaling: Shedding
light on novel therapeutic strategies. Int J Mol Sci. 21:60732020.
View Article : Google Scholar
|
|
8
|
McMellen A, Woodruff ER, Corr BR, Bitler
BG and Moroney MR: Wnt Signaling in gynecologic malignancies. Int J
Mol Sci. 21:42722020. View Article : Google Scholar
|
|
9
|
Gómez-Raposo C, Merino Salvador M, Aguayo
Zamora C, Garcia de Santiago B and Casado Sáenz E: Immune
checkpoint inhibitors in endometrial cancer. Crit Rev Oncol
Hematol. 161:1033062021. View Article : Google Scholar
|
|
10
|
Concin N, Creutzberg CL, Vergote I, Cibula
D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti
A, et al: ESGO/ESTRO/ESP guidelines for the management of patients
with endometrial carcinoma. Virchows Arch. 478:153–190. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cooper J and Giancotti FG: Integrin
signaling in cancer: Mechanotransduction, stemness, epithelial
plasticity, and therapeutic resistance. Cancer Cell. 35:347–367.
2019. View Article : Google Scholar
|
|
12
|
Park HJ, Park JE, Lee H, Kim SJ, Yun JI,
Kim M, Park KH and Lee ST: Integrins functioning in uterine
endometrial stromal and epithelial cells in estrus. Reproduction.
153:351–360. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lv Z, Yang Y and Yang C: Integrin α7
correlates with worse clinical features and prognosis, and its
knockdown inhibits cell proliferation and stemness in tongue
squamous cell carcinoma. Int J Oncol. 56:69–84. 2020.
|
|
14
|
Ge JC, Wang YX, Chen ZB and Chen DF:
Integrin alpha 7 correlates with poor clinical outcomes, and it
regulates cell proliferation, apoptosis and stemness via
PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma. Cell
Signal. 66:1094652020. View Article : Google Scholar
|
|
15
|
Xia D, Chen B and Yang X: Correlation of
integrin alpha 7 with clinicopathological characteristics and
survival profiles, as well as its regulatory role in cell
proliferation, apoptosis, and stemness in non-small-cell lung
cancer. J Clin Lab Anal. 33:e229732019. View Article : Google Scholar
|
|
16
|
Zhu T, Chen R, Wang J, Yue H, Lu X and Li
J: The prognostic value of ITGA and ITGB superfamily members in
patients with high grade serous ovarian cancer. Cancer Cell Int.
20:2572020. View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Wang J, Zhang C, Lin C, Zhang J,
Zhang W, Zhang W, Lu Y, Zheng L and Li X: Circular RNA circITGA7
inhibits colorectal cancer growth and metastasis by modulating the
Ras pathway and upregulating transcription of its host gene ITGA7.
J Pathol. 246:166–179. 2018. View Article : Google Scholar
|
|
19
|
Tian T, Lai X, Xiang K, Han X, Yin S,
Cabrera RM, Steele JW, Lei Y, Cao X, Finnell RH, et al:
Hypermethylation of PI3K-AKT signalling pathway genes is associated
with human neural tube defects. Epigenetics. 17:133–146. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao HD, Mao Y and Ying YG: The
involvement of the laminin-integrin α7β1 signaling pathway in
mechanical ventilation-induced pulmonary fibrosis. J Thorac Dis.
9:3961–3972. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Z, Kong X and Wang Z: Integrin α7
knockdown suppresses cell proliferation, migration, invasion and
EMT in hepatocellular carcinoma. Exp Ther Med. 21:3092021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi X, Wang J, Lei Y, Cong C, Tan D and
Zhou X: Research progress on the PI3K/AKT signaling pathway in
gynecological cancer (review). Mol Med Rep. 19:4529–4535.
2019.PubMed/NCBI
|
|
23
|
du Rusquec P, Blonz C, Frenel JS and
Campone M: Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor
positive HER2 negative advanced breast cancer. Ther Adv Med Oncol.
12:17588359209409392020. View Article : Google Scholar
|
|
24
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Zhang L, Zhang X and Cui Z:
PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial
cancer cells by inhibition of autophagy. Onco Targets Ther.
10:2865–2871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ni M, Zhao Y and Wang X: Suppression of
synuclein gamma inhibits the movability of endometrial carcinoma
cells by PI3K/AKT/ERK signaling pathway. Genes Genomics.
43:633–641. 2021. View Article : Google Scholar : PubMed/NCBI
|
